
Shares of Lumos Diagnostics LDX.AX more than double in value to A$0.080
Stock posts its biggest intraday pct gain since July 2023
Healthcare tech co signs U.S. distribution and supply agreement for FebriDx valued at up to $317 million
FebriDx is a rapid point of care test that helps clinicians differentiate between bacterial and non-bacterial acute respiratory infections through a fingerstick blood sample
Agreement signed with Hong Kong-headquartered PHASE Scientific International
About 15.8 million shares change hands, compared with the 30-day average volume of 663,247
YTD, shares up 108.6%